Study S002825

Zenagamtide Use for the Reduction of Risk of Major Adverse Cardiovascular Events in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07861100
Acronym: AMBIENCE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 8500
Start: 2026-10-26
Primary completion: 2030-09-16
Lead sponsor: Novo Nordisk A/S
Conditions: Cardiovascular Risk; Obesity
Interventions: DRUG:Zenagamtide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1335-0048; OTHER:2026-525182-53

Registered primary outcomes

Time from randomization to first occurrence of a 4-point (P) composite major adverse cardiovascular events (MACE) endpoint consisting of: Cardiovascular (CV) death, Non-fatal MI, Non-fatal stroke, HF hospitalization or urgent HF visit [From baseline (week 0) to up to 203 weeks or longer]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.